Mark G. Kris, MD

home / authors / mark-g-kris-md

Articles

March 11th 2022

Comprehensive Genomic Profiling in Community Oncology

Bruce Feinberg, DO Kenna R. Mills Shaw, PhD Mark G. Kris, MD Eugean Jiwanmall, MPH, MBA

Recommendations to address limitations in more widespread use of reflex testing in community oncology.

March 11th 2022

Future Outlook: Coverage for Comprehensive Genomic Profiling in Oncology

Bruce Feinberg, DO Eugean Jiwanmall, MPH, MBA Mark G. Kris, MD

How payers will support the use of comprehensive genomic profiling in oncology moving forward.

March 11th 2022

Future Outlook: Comprehensive Genomic Profiling in Oncology

Bruce Feinberg, DO Mark G. Kris, MD Kenna R. Mills Shaw, PhD Eugean Jiwanmall, MPH, MBA

Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.

March 4th 2022

Molecular Testing Turnaround Times and Treatment Decisions

Bruce Feinberg, DO Mark G. Kris, MD Kenna R. Mills Shaw, PhD

Variables that impact decisions to initiate therapy for solid tumor cancers versus wait for results of genomic profiling assays.

February 25th 2022

Comprehensive Genomic Profiling: When to Retest Patients

Bruce Feinberg, DO Mark G. Kris, MD Kenna R. Mills Shaw, PhD

Oncologists explain scenarios for which they may retest patients previously assessed via genomic profiling.

February 11th 2022

Comprehensive Genomic Profiling and Informed Decision-Making

Bruce Feinberg, DO Mark G. Kris, MD

How to determine what information from comprehensive genomic profiling assays is relevant vs extraneous when making treatment decisions for patients with solid tumor cancers.

February 11th 2022

Shifting Over to Comprehensive Genomic Profiling in Oncology

Bruce Feinberg, DO Mark G. Kris, MD Kenna R. Mills Shaw, PhD Eugean Jiwanmall, MPH, MBA

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

February 3rd 2022

Driver Mutations and Cancer Care

Bruce Feinberg, DO Mark G. Kris, MD

How the identification of certain driver mutations analyzed by genomic assays can be applied into oncology treatment.

January 28th 2022

Molecular Profiling Complexities and Coverage Decisions

Eugean Jiwanmall, MPH, MBA Bruce Feinberg, DO Mark G. Kris, MD

Considerations regarding coverage decisions to support the large amount of information provided by molecular testing assays and the validity of results in terms of clinical decision-making.